Atlas Trials

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety and Tolerability of Subcutaneous Elamipretide in Subjects With Intermediate Age-Related Macular Degeneration

Clinical trial NCT02848313 · COMPLETED

Trial details

NCT number
NCT02848313
Sponsor
Stealth BioTherapeutics Inc.
Status
COMPLETED
Phase
Phase 1
Study type
INTERVENTIONAL
Age-Related Macular Degeneration
Start date
2016-10-28
Primary completion
2018-03-16
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.